Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site-a Review

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2023 Jun 26

PMID 37359927

Authors

Aditi Bhatt

Suniti Mishra

Olivier Glehen

Affiliations

Soon will be listed here.

Abstract

Cancer of unknown primary (CUP) is a well-studied entity with guidelines available for the management of patients with CUP. The peritoneum represents one of the metastatic sites in CUP, and peritoneal metastases (PM) could present as CUP. PM of unknown origin remains a poorly studied clinical entity. There is only one series of 15 cases, one population-based study, and few other case reports on this subject. Studies on CUP, in general, cover some common tumour histological types like adenocarcinomas and squamous carcinomas. Some of these tumours may have a good prognosis though majority have high-grade disease with a poor long-term outcome. Some of the histological tumour types commonly seen in the clinical scenario of PM like mucinous carcinoma have not been studied. In this review, we divide PM into five histological types-adenocarcinomas, serous carcinomas, mucinous carcinomas, sarcomas and other rare varieties. We provide algorithms to identify the primary tumour site using immunohistochemistry when imaging, and endoscopy fails to establish the primary tumour site. The role of molecular diagnostic tests for PM or unknown origin is also discussed. Current literature on site-specific systemic therapy based on gene expression profiling does not show a clear benefit of this approach over empirical systemic therapies.

References

Klein C . Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4):302-12. DOI: 10.1038/nrc2627. View

Jaffee I, Rahmani M, Singhal M, Younes M . Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006; 130(10):1522-6. DOI: 10.5858/2006-130-1522-EOTITF. View

Banik T, Halder D, Gupta N, Dey P . Malignant mixed Müllerian tumor of the uterus: diagnosis of a case by fine-needle aspiration cytology and review of literature. Diagn Cytopathol. 2011; 40(7):653-7. DOI: 10.1002/dc.21681. View

Elias D, Lefevre J, Duvillard P, Goere D, Dromain C, Dumont F . Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think. Ann Surg. 2009; 251(2):307-10. DOI: 10.1097/SLA.0b013e3181bdf8cf. View

Fitzpatrick D, Carr I, McLaren L, Leek J, Wightman P, Williamson K . Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet. 2003; 12(19):2491-501. DOI: 10.1093/hmg/ddg248. View

Franko J, Shi Q, Meyers J, Maughan T, Adams R, Seymour M . Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016; 17(12):1709-1719. DOI: 10.1016/S1470-2045(16)30500-9. View

Diaz L, Okonkwo A, Solans E, Bedrossian C, Rao M . Extensive myxoid change in well-differentiated papillary mesothelioma of the pelvic peritoneum. Ann Diagn Pathol. 2002; 6(3):164-7. DOI: 10.1053/adpa.2002.33902. View

Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H . Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997; 57(23):5379-85. View

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

10.

Liu Y, Ishibashi H, Hirano M, Takeshita K, Mizumoto A, Ichinose M . Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus. Ann Surg Oncol. 2015; 22(8):2799-805. DOI: 10.1245/s10434-014-4336-8. View

11.

Goldstein N, Bassi D . Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001; 115(5):695-702. DOI: 10.1309/1NCM-46QX-3B5T-7XHR. View

12.

Kato S, Krishnamurthy N, Banks K, De P, Williams K, Williams C . Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017; 77(16):4238-4246. PMC: 5729906. DOI: 10.1158/0008-5472.CAN-17-0628. View

13.

Atkins K, Arronte N, Darus C, Rice L . The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol. 2007; 32(1):98-102. DOI: 10.1097/PAS.0b013e3181574d1e. View

14.

Thomassen I, Verhoeven R, van Gestel Y, van de Wouw A, Lemmens V, de Hingh I . Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown origin. Eur J Cancer. 2013; 50(1):50-6. DOI: 10.1016/j.ejca.2013.08.009. View

15.

Tornos C, Soslow R, Chen S, Akram M, Hummer A, Abu-Rustum N . Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005; 29(11):1482-9. DOI: 10.1097/01.pas.0000176429.88702.36. View

16.

Liu H, Shi J, Wilkerson M, Lin F . Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012; 138(1):57-64. DOI: 10.1309/AJCP5UAFMSA9ZQBZ. View

17.

Gatalica Z, Millis S, Vranic S, Bender R, Basu G, Voss A . Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget. 2014; 5(23):12440-7. PMC: 4322997. DOI: 10.18632/oncotarget.2574. View

18.

Pillai R, Deeter R, Rigl C, Nystrom J, Miller M, Buturovic L . Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn. 2011; 13(1):48-56. PMC: 3070545. DOI: 10.1016/j.jmoldx.2010.11.001. View

19.

Rajeev R, Turaga K . Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis. Cancer Control. 2016; 23(1):36-46. DOI: 10.1177/107327481602300107. View

20.

Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S . Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000; 19(2):158-63. DOI: 10.1097/00004347-200004000-00010. View